skip to Main Content

BCS’s Bedside PEWS™ covered in Hospital News

BCS Logo for web
Bedside Clinical Systems and their flagship product, Bedside PEWS™, were featured in the February 2014 issue of Hospital News.

Bedside Clinical Systems‘ (BCS) flagship product, the Bedside Paediatric Warning System or BedSidePEWS, was covered in the February 2014 edition of Hospital News.

The article, written by Rajesh Sharma who is president and CMO of BCS, explains how the technology helps decrease the amount of code blues in paediatric patients.

Invented by Dr. Christopher Parshuram of the Hospital of Sick Children (SickKids), Bedside PEWS™ is now in three hospitals in Canada, the United States and New Zealand. The technology received FDA approval last year.

Here’s an excerpt from the article:

The program digitally logs, charts, and evaluates seven vital sign items thst sre part of routine clinical assessments and then summarizes them into a singly score. From the BedsidePEWS score, care providers can better match the level of care with the patient’s required needs, thereby improving patient outcomes and reducing the number of urgent calls, code blue incidents and related deaths.

“Identifying at-risk patients is significant since approximately 5,000 children in North America experience a code blue event each year, from which too many children die or sustain neurological deficit. BedsidePEWS hopes to improve outcomes for these patients and their families,” says Dr. Parshuram.

Continue Reading

CAMH, Assurex Health Partner to Bring Personalized Care to More Canadians

The Centre for Addiction and Mental Health and Assurex Health combine resources to bring personalized medicine in psychiatry, reducing the current trial-and-error approach

TORONTO – The Centre for Addiction and Mental Health (CAMH), Canada’s leading hospital for mental health, and Assurex Health, a global leader in personalized medicine, have signed an agreement for a joint venture to bring the benefits of this treatment approach to more Canadians.

Centre for Addiction and Mental Health (CAMH) Logo

The personalized approach helps to match the right medication at the right dose for each patient, based on their genetic makeup. Using Assurex Health’s GeneSight panel, physicians can easily see which psychiatric medications are likely to be effective for each patient and which ones are not, often avoiding treatment failure and side effects.

“This partnership between CAMH and Assurex Health is essential to advance the widespread use of personalized medicine in psychiatry, and improve health care for Canadians who need medications for mental health problems,” said Dr. James Kennedy, head of the Tanenbaum Centre for Pharmacogenetics at CAMH. This approach is a game-changer from the current trial-and-error approach to prescribing, which results in many patients having to try different psychiatric medications, each with potential side-effects, before the best medication for them can be determined.

AssureRx Canada (ARxC) has been established as a subsidiary of the U.S. company, with its Canadian office and laboratory on CAMH premises. Assurex Health will provide backing for ARxC operations. CAMH holds a minority equity share in AssureRx Canada and will receive royalties on the sale of genetic tests that incorporate CAMH-discovered genetic markers.

Continue Reading
Back To Top